Updated:
Iter Investments
Iter Investments is a venture capital firm focused on supporting emerging companies within the psychedelic ecosystem of behavioral and mental health.
Iter Investments
Iter Investments is a venture capital firm focused on supporting emerging companies within the psychedelic ecosystem of behavioral and mental health.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Fort Lauderdale
Corporate office
Fort Lauderdale, FL, United States
Sector focus
Frequently asked questions
What is Iter Investments' specific investment focus?
Iter Investments is a venture capital firm exclusively focused on the psychedelic medicine and mental health sector. The firm invests in early-stage companies across the value chain, including drug discovery platforms, clinical research organizations, and the clinic networks that administer psychedelic-assisted therapies.
Does Iter Investments manage a fund structure or is it structured as a single-family office?
Iter Investments operates as an asset manager, not a single-family office. The firm deploys external capital into venture-stage opportunities within the psychedelic medicine ecosystem.
Which portfolio companies have been publicly linked to Iter Investments?
Publicly disclosed portfolio positions include atai Life Sciences, a clinical-stage biopharmaceutical platform developing multiple psychedelic compounds. The firm also targets specialized treatment-clinic operators and drug-discovery ventures, though the full portfolio is not publicly detailed.
Is Iter Investments committed only to direct venture investments?
The firm is known for direct equity investments in early-stage companies. There is no public record indicating the firm takes fund-of-funds positions or participates in SPVs for secondaries within the psychedelic medicine sector.
What jurisdictions does Iter Investments focus on?
Iter Investments deploys capital primarily in North America and Europe. These regions have the most advanced regulatory frameworks for psychedelic-assisted therapies, which reduces binary legal risk for the clinic networks and drug developers the firm backs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: